Aggarwal A N, Behera D
Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Expert Opin Pharmacother. 2000 Dec;1(7):1423-7. doi: 10.1517/14656566.1.7.1423.
Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive disease with inadequate response to conventional treatment with corticosteroids and/or immunosuppressive agents in most patients. Interferon-gamma (IFN-gamma), an antifibrotic agent, has been proposed as a novel therapeutic approach. Several investigators have shown a relative decrease in systemic and pulmonary IFN-gamma activity in patients with IPF. Experimental evidence from animal and human studies also suggests that IFN-gamma administration may ameliorate lung fibrosis. Clinical experience is, however, limited to a single clinical trial that showed objective functional improvement in a small number of patients treated with IFN-gamma and low-dose corticosteroids. Further research is needed to characterise the efficacy, safety and optimum route of administration of this agent before it can be recommended for use in routine clinical practice.
特发性肺纤维化（IPF）是一种进行性疾病，大多数患者对常规使用皮质类固醇和/或免疫抑制剂治疗反应不佳。干扰素-γ（IFN-γ）作为一种抗纤维化药物，已被提出作为一种新的治疗方法。一些研究人员发现，IPF患者的全身和肺部IFN-γ活性相对降低。动物和人体研究的实验证据也表明，给予IFN-γ可能改善肺纤维化。然而，临床经验仅限于一项临床试验，该试验显示，少数接受IFN-γ和低剂量皮质类固醇治疗的患者有客观的功能改善。在推荐该药物用于常规临床实践之前，还需要进一步研究以确定其疗效、安全性和最佳给药途径。
